MycoBiomDB – Record Details (MyCo_5179)

Biomarker Record Details

Database ID: MyCo_5179
DB IDMyCo_5179
TitleMonitoring of extracellular matrix metabolism and cross-linking in tissue, serum and urine of patients with chromoblastomycosis, a chronic skin fibrosis
Year1998
PMID9767374
Fungal Diseases involvedChromoblastomycosis
Associated Medical ConditionDermal fibrosis
GenusFonsecaea
Speciespedrosoi
OrganismFonsecaea pedrosoi
Ethical StatementThe study was approved by the Malagasy Ministry of Health and was conducted arrording to the ethical requirements.
Site of InfectionNone
Opportunistic invasiveNone
Sample typeBody fluid
Sample sourceUrine
Host GroupHuman
Host Common nameHuman
Host Scientific nameHomo sapiens
Biomarker NamePyridinoline
Biomarker Full NamePyridinoline
Biomarker TypeDiagnostic
BiomoleculeMetabolite
Geographical LocationMalagasy
CohortThe trial design included treatment with terbinafine (Lami sil, Novartis, Rueil-Malmaison, France) 500 mg daily for 1 year. The efficiency of the treatment was evaluated by examination of skin scrapings, mycological cultures or histopathology.
Cohort No.None
Age GroupNone
P Valuep=0.04
SensitivityNone
SpecificityNone
Positive Predictive ValueNone
MICNone
Fold ChangeNone
PathwayNone
Disease Introduction MechanismChromoblastomycosis is a cutaneous fungal infection characterized by dermal fibrosis, and worldwide this debilitating disease is most endemic in Madagascar. This chronic mycosis begins with one or more nodules that subsequently develop a verrucous or papillomatous lesion, often with superimposed bacterial infection. Histological examination reveals a granulomatous reaction associated with a pseudoepitheliomatous hyperplasia of the epidermis.
TechniqueLiquid chromatography
Analysis MethodMetabolomics Approach
ELISA kitsNone
Assay DataNone
Validation Techniques usedMetabolomics Approach
Up Regulation Down RegulationIncrease
Sequence DataNone
External LinkNone